Experimental study points to systemic sclerosis treatment

by Cedars-Sinai Medical Center

edited by Sadie Harley, reviewed by Andrew Zinin

Sadie Harley

Scientific Editor

Meet our editorial team
Behind our editorial process

Andrew Zinin

Chief Editor

Meet our editorial team
Behind our editorial process Editors' notes

This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:

fact-checked

peer-reviewed publication

trusted source

proofread

The GIST Add as preferred source

Investigators at Cedars-Sinai Health Sciences University used an experimental drug to reverse the effects of systemic sclerosis, a serious autoimmune disease. The study, conducted in a laboratory, was published in JCI Insight.

Systemic sclerosis, also called scleroderma, is a chronic, life-threatening condition that scars the skin, lungs, heart and other organs. Because there is no cure or known cause for the disease, which affects about 100,000 people in the U.S., treatments focus on relieving symptoms.

"That's why we are so excited about our findings," said Eduardo Marbán, M.D., Ph.D., executive director of the Smidt Heart Institute at Cedars-Sinai and corresponding author of the study. "The basic immune-system pathway driving systemic sclerosis is blocked by this new drug, making it a potential future therapy."

Investigators tested the experimental drug, called TY1, on immune cells collected from patients with systemic sclerosis. They found that the drug reduced inflammation and DNA damage in those cells. When they administered TY1 to laboratory mice with a condition that mimics systemic sclerosis, investigators found that heart function and physical activity improved, and scar formation in organs was reduced.

TY1, which was developed at Cedars-Sinai, is a synthetic version of a type of noncoding ribonucleic acid (RNA), a molecule that regulates cellular processes. After using TY1 to reduce tissue damage in laboratory experiments addressing heart attacks, as reported last year, investigators sought to determine whether TY1 might have a similar effect on autoimmune disorders.

"We chose to test TY1 in systemic sclerosis because the science of how the drug works makes sense and also because it is such a devastating disease," said Ahmed Ibrahim, Ph.D., associate professor of cardiology at Cedars-Sinai and a co-investigator of the study.

Investigators are currently preparing an investigational new drug application to the U.S. Food and Drug Administration, the first step toward obtaining approval to study TY1 in people with systemic sclerosis.

"This innovative study illustrates how doing careful research on one disease can lead to key discoveries in another—in this case, from conditions that can stiffen the heart to scleroderma, a rare disease that hardens the skin and internal organs in patients who have waited decades for better treatment options," said Susan Cheng, M.D., chair of the Department of Cardiology in the Smidt Heart Institute.

Publication details

Noncoding RNA TY1 reverses fibrosis in systemic sclerosis by attenuating the cGAS-STING pathway, JCI Insight (2026). DOI: 10.1172/jci.insight.197716

Journal information: JCI Insight

Key medical concepts

Systemic sclerodermaDNA DamageInflammation

Clinical categories

RheumatologyClinical pharmacology Provided by Cedars-Sinai Medical Center Who's behind this story?

Sadie Harley

BSc Life Sciences & Ecology. Microbiology lab background with pharmaceutical news experience in oil, gas, and renewable industries. Full profile →

Andrew Zinin

Master's in physics with research experience. Long-time science news enthusiast. Plays key role in Science X's editorial success. Full profile →

Citation: Experimental study points to systemic sclerosis treatment (2026, September 8) retrieved 8 September 2026 from https://medicalxpress.com/news/2026-09-experimental-sclerosis-treatment.html This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.